Novo Nordisk Must Face Shareholder Fraud Claims Over CagriSema Disappointment

How CagriSema’s Missed Target Triggered a Shareholder Lawsuit

A U.S. federal judge has allowed a shareholder lawsuit to proceed against Novo Nordisk, centering on claims that the Danish drugmaker misled investors about its next-generation obesity treatment, CagriSema. The decision follows a dramatic market reaction in December 2024, when Novo Nordisk’s American depositary receipts plunged 17.8% after the company disclosed that CagriSema delivered only 20.4% average weight loss—falling short of its own 25% target and the 22.5% benchmark set by Eli Lilly’s rival drug Zepbound.

The lawsuit, brought by ADR investors, argues that Novo Nordisk and then-development chief Martin Holst Lange intended to defraud shareholders by implying that the CagriSema trial’s dosing protocols were consistent with prior studies. In reality, the company allowed participants to self-manage their dosage, resulting in just 57% reaching the highest dose—a deviation that raised immediate tolerability concerns. Judge Robert Kirsch in Trenton, New Jersey, ruled that the complaint adequately alleges intent to deceive regarding those tolerability statements, while dismissing a swath of other claims, including those tied to the use of “fixed doses” and “aspirational” weight-loss projections.

The ruling keeps the core of the securities fraud case alive, even as it does not address the merits of the surviving claims. The legal battle unfolds against a backdrop of fierce commercial rivalry: just a month before this decision, Novo Nordisk sued Eli Lilly over comparative advertising for Zepbound and Mounjaro, with a key injunction hearing scheduled for August 27. The shareholder suit now adds a second front to Novo Nordisk’s litigation calendar, testing whether its obesity pipeline—once heralded as Wegovy’s heir—can sustain investor trust.

What the CagriSema Shortfall Means for Novo Nordisk and the Obesity Drug Race

Novo Nordisk’s Legal Exposure

The survival of the fraud claim tied to tolerability is a significant setback for Novo Nordisk. While Judge Kirsch dismissed many alleged misstatements—including stock-moving references to “fixed doses”—the finding that a senior executive’s statements could be read as intentionally misleading keeps the company on the hook for potentially substantial damages. The distinction matters: a case built on aspirational goals is far weaker for plaintiffs than one that questions the transparency of dosing protocols, which go directly to patient safety and commercial viability. Novo Nordisk must now decide whether to fight to a possible trial, a process that could surface internal communications about the Redefine 1 trial design, or to seek a settlement that would avoid that scrutiny but could be costly.

Eli Lilly Gains Competitive Ground

The CagriSema miss has reshaped the competitive dynamics in the lucrative obesity market. Eli Lilly’s Zepbound had already demonstrated a 22.5% weight reduction, a result widely seen as “proven” by investors. By falling short of that benchmark, CagriSema handed Lilly a clear marketing advantage, reinforced by Novo Nordisk’s own lawsuit seeking to halt Lilly’s comparative ads. The dueling legal actions—a shareholder fraud suit against Novo and its own advertising injunction request against Lilly—are now coloring the commercial battle. Even if CagriSema eventually secures approval, the tolerability questions and missed efficacy target will likely force Novo to invest heavily in proving the drug’s real-world value, while Lilly is free to consolidate its lead with Zepbound and Mounjaro.

Pipeline Credibility at Stake

Investors and analysts had pinned hopes on Redefine 1 as proof that Novo Nordisk could deliver a strong anti-obesity franchise beyond Wegovy. The 20.4% result—and the revelation that only a fraction of participants reached the highest dose—undermined the narrative of a reliable, best-in-class pipeline. The shareholder suit amplifies that damage by raising questions about whether management was candid about the trial’s design. For a company that has built its valuation on obesity drug dominance, the combination of a clinical miss and an ongoing fraud case may lead investors to discount future pipeline assets until Novo Nordisk provides clear, externally validated data on tolerability and efficacy.

Investor Checklist After the CagriSema Ruling

• Track the August 27 injunction hearing: The outcome of Novo Nordisk’s own lawsuit against Eli Lilly over comparative advertising will directly impact the competitive landscape. A ruling that halts Lilly’s ads could relieve some pressure on CagriSema’s market positioning.
• Watch for case scheduling in the shareholder lawsuit: The judge has not yet set a trial date; investors should monitor docket updates for class certification motions or settlement discussions. Any indication of settlement size or scope will be a pricing catalyst for Novo’s ADRs.
• Assess next pipeline milestones: Novo Nordisk’s ability to restore confidence hinges on forthcoming data from advanced obesity candidates or a new trial design for CagriSema. Pay attention to scientific conference presentations and FDA interactions that signal a credible path forward.